{"title":"静脉注射免疫球蛋白和利妥昔单抗成功治疗顽固性幼年叶面天疱疮","authors":"H. Teo, T. Lim, K. Leong, P. Muniandy","doi":"10.4103/ijpd.ijpd_171_21","DOIUrl":null,"url":null,"abstract":"Pemphigus foliaceus (PF) is uncommon among children. The usage of rituximab in childhood PF is even less documented. We reported a case of a 16-year-old boy with juvenile PF who failed conventional treatments and was started on combination therapy of intravenous immunoglobulin (IVIG) and rituximab followed by six-monthly rituximab maintenance therapy. He achieved full remission and no adverse effects. Therefore, in cases of recalcitrant juvenile PF, combination therapy of IVIG and rituximab can be considered.","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"23 1","pages":"245 - 248"},"PeriodicalIF":0.2000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Successful treatment of recalcitrant juvenile pemphigus foliaceus with intravenous immunoglobulin and rituximab\",\"authors\":\"H. Teo, T. Lim, K. Leong, P. Muniandy\",\"doi\":\"10.4103/ijpd.ijpd_171_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pemphigus foliaceus (PF) is uncommon among children. The usage of rituximab in childhood PF is even less documented. We reported a case of a 16-year-old boy with juvenile PF who failed conventional treatments and was started on combination therapy of intravenous immunoglobulin (IVIG) and rituximab followed by six-monthly rituximab maintenance therapy. He achieved full remission and no adverse effects. Therefore, in cases of recalcitrant juvenile PF, combination therapy of IVIG and rituximab can be considered.\",\"PeriodicalId\":13275,\"journal\":{\"name\":\"Indian Journal of Paediatric Dermatology\",\"volume\":\"23 1\",\"pages\":\"245 - 248\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Paediatric Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijpd.ijpd_171_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Paediatric Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijpd.ijpd_171_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Successful treatment of recalcitrant juvenile pemphigus foliaceus with intravenous immunoglobulin and rituximab
Pemphigus foliaceus (PF) is uncommon among children. The usage of rituximab in childhood PF is even less documented. We reported a case of a 16-year-old boy with juvenile PF who failed conventional treatments and was started on combination therapy of intravenous immunoglobulin (IVIG) and rituximab followed by six-monthly rituximab maintenance therapy. He achieved full remission and no adverse effects. Therefore, in cases of recalcitrant juvenile PF, combination therapy of IVIG and rituximab can be considered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
